Gotrade News - CrowdStrike shares fell even after the cybersecurity firm posted a strong earnings beat and announced a stock split. In the same session, Eli Lilly surged to a record high on promising weight-loss trial data.
These opposing reactions capture a nuanced earnings stretch for global investors watching US equities. The after-hours session featured several reporters, yet these two large caps dominated market attention.
Key Takeaways
- CrowdStrike grew revenue 26% and announced its first 4-for-1 stock split, yet the stock still slid roughly 10%.
- Eli Lilly rose 1.57% to a record $1,149.15 after Phase 3 retatrutide data showed an average 70-pound loss at the highest dose.
- A premium valuation and slowing net new ARR were the main reasons investors stayed cautious on CrowdStrike.
CrowdStrike Strong but Pricey
According to The Motley Fool, CrowdStrike reported fiscal Q1 2027 revenue up 26% with non-GAAP EPS climbing about 50%. The results beat expectations and prompted management to raise full-year guidance.
The company also announced its first-ever 4-for-1 stock split as a public company. Such moves typically make the per-share price more accessible to retail investors.
Even so, shares of CrowdStrike (CRWD) fell roughly 10% after the report. The drop came shortly after the stock hit an all-time high on June 1.
As reported by The Motley Fool, net new ARR reached a fiscal Q1 record of $256 million, up 32%. That figure marked a step down from 47% growth the prior quarter.
Ending ARR rose 24% to $5.51 billion across the period. The AI Detection and Response segment grew more than 250% sequentially, with its pipeline exceeding $50 million.
Despite solid fundamentals, valuation remains the chief concern for a portion of investors. The stock's forward P/E exceeds 100x after a roughly 40% rally year-to-date.
"What I see is AI driving structural demand for cybersecurity that compounds, not decelerates," said CEO George Kurtz. The remark underscored management's conviction in the long-term outlook.
Eli Lilly Sets a New Record
By contrast, shares of Eli Lilly (LLY) rose 1.57% to a record $1,149.15. The pharmaceutical giant's market capitalization now stands at $1.1 trillion.
Per The Motley Fool, the catalyst was positive Phase 3 results for retatrutide, a once-weekly injectable weight-loss drug. The highest 12 mg dose averaged 70 pounds lost, or 28% of body weight, over 80 weeks.
The lowest 4 mg dose still trimmed an average 47 pounds, equal to 19% of body weight. The study also noted improvements in knee pain, sleep apnea, and type 2 diabetes.
"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time," said Dr. Ania Jastreboff. The global obesity market itself is estimated at $200 billion.
Sector sentiment sharpened as rival Zealand Pharma fell on negative safety data the same day. Investors seeking broad exposure can watch Invesco QQQ Trust (QQQ) as a Nasdaq earnings-season proxy.
Sources
